The non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) - receptor antagonist perampanel (PER) was approved in 2015 for treatment of primary generalized tonic-clonic seizures (pGTCS). The aim of this narrative review is to summarize available data on pharmacological properties, efficacy and tolerability of PER in pGTCs.
|Titolo:||Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy|
|Data di pubblicazione:||2016|
|Appare nelle tipologie:||01.01 Articolo in Rivista|